Catalent completes $4.6 million expansion at Singapore clinical supply facility and marks 20 years in the region.
Catalent Pharma Solutions announced on Feb. 28, 2018 the completion of a two-year, $4.6 million expansion at its Singapore clinical supply facility. The expansion added GMP space for secondary packaging, doubled ambient storage, and quadrupled cold storage capacity at the site. The site, which has almost tripled in size since opening in 1998, measures almost 20,000-sq. ft. and is described by the company as a key strategic hub in its Asia-Pacific network and global clinical supply business.
“We are particularly pleased to have completed the expansion in a year that marks the 20th anniversary of what was Catalent’s first facility in the Asia-Pacific region,” said Bernie Clark, VP Marketing, Catalent Clinical Supply Services in a company press release. “Supported by many long-serving employees, the Singapore site has undergone tremendous growth over the past two decades and now routinely distributes to 18 countries in the region.”
The company has facilities in the United States, United Kingdom, Germany, Japan, and China, and more than 50 audited depots.
Source: Catalent Pharma Solutions
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.